Oracle's stock has plunged since hitting an all-time high in September as the company has become a poster child for growing investor concerns that an AI bubble has formed. The company is enmeshed in ...
Oracle's market value has dropped by over $300 billion since its OpenAI deal. Investors are worried about the company's debt-fueled AI investments. This has led to talk of a 'Curse of ChatGPT'. Oracle ...
Simply sign up to the Technology sector myFT Digest -- delivered directly to your inbox. It’s too soon to be talking about the Curse of OpenAI, but we’re going to anyway. Since September 10, when ...
Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...
The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...
CEO Narasimhan says no tariff impact on guidance Top-selling heart drug Entresto sees growth stall Older drugs hit by 'generic erosion' in US market Newer drugs help offset some of the slowdown ...
Foundation models excel at clerical work but fail at construction blueprints, banking compliance, and healthcare workflows—Oracle bets vertical knowledge is the gap At Oracle AI World in Las Vegas ...
The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...
Sept 10 (Reuters) - Oracle (ORCL.N), opens new tab shares surged about 43% to a record high on Wednesday, putting the company on track to join the elite trillion-dollar club and propelling co-founder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback